Scrip's Executive Briefings
Scrip's Executive Briefings provide in-depth analyses of issues of strategic interest to the pharmaceutical and biotech industries. They span business strategy, innovation in pharmaceutical R&D, country overviews and developments in healthcare policy. Executive Briefings are designed to provide analytical and business-critical information in a clear and accessible format.
 | ||||||||||||||||||||
| ||||||||||||||||||||
 | ||||||||||||||||||||
 | | |||||
Pharma: Embrace your Companions December 2011 "The application of personalised medicine is likely to improve patient care as well as lower healthcare costs." These words were part of the founding mission statement of EPEMED, the European association for clinicians, SME biotechs and major pharma and diagnostic companies. The association was formed in August 2009 to provide a platform for harmonisation in the development and implementation of value-based diagnostics across Europe...Read more |
Capital Efficiency: Managing biotechs in straitened times December 2011 At first glance, 2011 looks like it has been a bumper year for biotech financing. The industry has raised $40 billion plus from the capital markets and yet the amount of money being put to work in innovative pre-commercial biotechs is stagnating at around $5 billion. At the beginning of December, Scrip Intelligence hosted a roundtable discussion, chaired by editor-in-chief Mike Ward, involving Dr Kevin Johnson, partner at Index Ventures, Dr Robert Burns, CEO at 4-Antibody, Dr Johanna Holldack, CEO at Telormedix, and Dr Jason Slingsby, CEO at ProtAffin, to discuss the pressures facing the biotech industry. | |||||
 | |
| |||||||
| |||||||
| | |||
Adopting Orphans: October 2011 Watch the Scrip Roundtable debate to understand the opportunities and challenges for the pharmaceutical industry as it seeks to create value and deliver novel medicines to patients in the orphan drugs space. |  How to leverage IndiaMerck tailors emerging market strategies July 2011 By 2013, Merck & Co wants the leading emerging markets to account for a quarter of its revenues, representing a 50% hike from 2010. Dr Merv Turner, Merck's chief strategy officer, explains to Mike Ward how the company, currently ranked fifth in emerging markets, plans to hit such an ambitious target.... Read more | |||
| |
| | |||||||||||||||
Cancer vaccines June 2011 Scrip's fourth roundtable event, 'Cancer vaccines', was held at Prospero House, London on 7 June 2011. Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip's editor-in-chief Mike Ward. |
June 2011
| |||||||||||||||
| |
| ||||||
| ||||||
| | |||
 Lessons in Lifecycle ManagementMarch 2011 Lessons in Lifecycle Management is our new quick-reference collection of 50 drug case studies from the recent history of some of the world's leading pharma companies. This is not an encyclopaedia of every lifecycle strategy, but an attempt to generate timely intelligence on the planning and nurturing of product lifecycles... Read more |
November 2010
Six industry experts, representing big pharma, the CRO sector, HTA bodies and health economists, debated the growing influence of payers across the world's major pharmaceutical markets. | |||
| |
| | |
Welcome to the Scrip Intelligence microsite on Australia, a repository of pharmaceutical information, analysis and multimedia features that will give you business insight into a country worth some 10 blockbusters (or $10 billion) and expected to reach $13 billion in 2014. Read more |
President Barack Obama's commitment to health reform was unmistakeable in February 2009, when he launched a budget plan that confirmed that an overhaul of US healthcare was to be the centrepiece of his first year in office. 16 years after his Democratic predecessor Bill Clinton tried – and failed – to rebuild US healthcare by introducing into Congress a fait accompli plan, Mr Obama took another route: a consultative approach, in which, once the proposal was made, Congress would hammer out the details... Read more | |
| |
| | |
Mind over matter: prospects for the CNS market
|
| |
| |
